Tursi 2007a.

Methods	RCT, single‐centre, Italy
Participants	30 patients with uncomplicated acute diverticulitis after remission, mean 60.1 years, 19 males, 11 female
Interventions	5‐ASA balsalazide 2.25 g once daily for 10 days every month plus probiotic VSL#3 450 billions/d for 15 days every month vs probiotic alone (VSL#3) 450 billions/d for 15 days every month. Remission was induced with rifaximin 800 mg/d and 5‐ASA 2.25 g/d for 10 days. Follow‐up: 12 months
Outcomes	Maintainence of remission after an attack, overall scores at end of follow‐up, single symptom assessment, adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	"the patients who met inclusion criteria were enrolled in the study and randomised, in an unblinded fashion, one to one into the two groups of treatments, after giving their informed consent" It is likely allocation was not concealed.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Randomised in an "unblinded" fashion. Treatment regimens were different, no placebo was used, likely participants and physicians were not blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described but probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	One participant from each group lost to follow‐up
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	None found

5‐ASA: 5‐aminosalicylic acid.
 ITT: intention‐to‐treat.
 RCT: randomised controlled trial.
 TIQ: Therapeutic Impact Questionnaire.